Avidity Biosciences, Inc. is a pioneering biopharmaceutical company dedicated to revolutionizing treatment modalities using its unique platform based on antibody oligonucleotide conjugates (AOCs™). AOCs are essentially therapeutic proteins conjugated with therapeutic RNA molecules capable of targeting specific cells. Founded in 2013, Avidity Biosciences has its headquarters stationed in La Jolla, California.
Avidity Biosciences is leveraging the power of antibody-drug conjugate technology, synergizing it with RNA therapeutics – a disruptive new dimension in the world of medicine. This union creates a multi-modal opportunity to create ‘potent’ therapeutics. The company's advanced technology allows them to develop transformative medicines for diseases that were once considered untreatable. Currently, Avidity Biosciences has become known for its work on myotonic dystrophy type 1 (DM1) and other muscle-related disorders with considerable unmet medical needs.
AOCs, Avidity's proprietary method, transports oligonucleotides in the body with significantly higher efficacy. This technology makes it possible to address diseases at the genetic level, a capability that further differentiates Avidity in the field of biopharmaceutical companies.
Avidity has gathered an expert team who carry the combined knowledge of antibody engineering, conjugation chemistry, and oligonucleotide therapies. The team of experienced professionals includes individuals who have made groundbreaking advancements in the field of RNA therapies.
In June 2020, Avidity Biosciences completed its initial public offering (IPO), which highlights the interest and investment potential of its unique blend of technologies. The company is focused on scientific discovery and drug development, with an open alliance model that effectively encourages partnerships with academia and other biotechnology and pharmaceutical companies.
Despite being a relatively young company, Avidity Biosciences, Inc. has made significant strides in creating innovative therapeutics, showing its potential to contribute to the future of medicine. As the company continues to develop and refine its technologies, it aims to produce transformative therapies for patients with limited treatment options. With the AOCs technology providing a league of advanced capabilities, Avidity Biosciences is poised to revolutionize the developmental therapeutics industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Steven George Hughes, CMO of Atrium Therapeutics, Inc., reported a tax-related share withholding on RSU vesting. On September 18, 2026, 21,459 common stock shares were withheld at $8.95 each to satisfy tax obligations from the vesting of restricted stock units. After this transaction, Hughes retains direct ownership of 51,638 common stock shares.
Atrium Therapeutics, Inc. (RNA) shows a substantial potential upside of 141.31% according to analyst consensus. This biopharmaceutical company focuses on RNA therapeutics for cardiomyopathies, backed by collaborations with industry leaders like Bristol-Myers Squibb and Eli Lilly. Despite being a development-stage firm with current revenue declines, analysts maintain a "buy" rating with a $25.00 price target, highlighting its speculative yet promising growth prospects in the biotech sector.
Atrium Therapeutics, Inc. announced its participation in several upcoming investor conferences in September, including the Wells Fargo 21st Annual Healthcare Conference, the 2026 Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. The company, a biopharmaceutical firm developing RNA therapeutics for heart conditions, highlighted recent progress such as FDA clearance for ATR-1072 for PRKAG2 syndrome and the launch of its Corventis™ Phase 1/2 clinical trial. Details for webcasts of these events will be available on Atrium's investor relations website.